TrialBlood2020

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.

Vaishali Sanchorawala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.